不适合临床试验患者的原发性乳腺癌冷冻消融:多机构研究
这项多机构回顾性研究纳入112例因患者或肿瘤特征不适合冷冻消融临床试验而接受无手术切除冷冻消融的原发性单灶乳腺癌女性,中位随访2.0年,6.3%发生轻微不良事件,98.2%技术成功,10.9%出现同侧乳腺肿瘤复发,1、2、3年累积复发率分别为5.3%、12.2%、18.2%。作者认为对选择性不适合手术的患者,冷冻消融是安全的替代选择且结局良好。
要点
- 112例不适合临床试验的原发性乳腺癌患者接受冷冻消融,98.2%技术成功,无中度或重度不良事件。
- 中位随访2.0年,10.9%出现同侧乳腺肿瘤复发,其中7例真性复发、5例新原发。
- 同侧乳腺肿瘤复发1、2、3年累积发生率分别为5.3%、12.2%、18.2%(死亡作为竞争风险)。
核心结论
- 在经选择的患者或肿瘤特征不佳的个体中,乳腺癌冷冻消融提供了安全的手术替代方案且结局良好;这些发现可能对同时为手术条件差的患者尤其相关。
研究设计与样本
- 回顾性研究,纳入7家机构2000年1月1日至2021年8月26日期间因不适合(因而被排除于)冷冻消融临床试验而接受活检证实单灶原发性乳腺癌冷冻消融(以局部治愈为目的、无手术切除)的女性,最终样本112例(中位年龄71岁)。
诊断标准与关键数值
- 技术成功定义为未提前终止且达到预期治疗参数、首次随访影像检查无残留病变证据;112例中110例(98.2%)技术成功。
临床应用与阅片要点
- 作者认为在经选择的患者或肿瘤特征不佳的个体中,乳腺癌冷冻消融提供了安全的手术替代方案且结局良好,这些发现可能对同时为手术条件差的患者尤其相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Breast cancer cryoablation clinical trials have strict inclusion criteria that exclude patients with potentially treatable disease. OBJECTIVE. The purpose of this study was to evaluate the safety and outcomes of breast cancer cryoablation without surgical excision in patients ineligible for prospective cryoablation clinical trials due to unfavorable patient or tumor characteristics. METHODS. This retrospective study included women who underwent cryoablation of biopsy-proven unifocal primary breast cancer with locally curative intent, without surgical excision, despite being ineligible for (and thus excluded from) cryoablation clinical trials, across seven institutions between January 1, 2000, and August 26, 2021. Adverse events (AEs) were recorded. Cryoablation procedures were classified as technically successful if they were not prematurely terminated and achieved intended treatment parameters and if the first follow-up imaging examination showed no evidence of residual disease. The results of follow-up biopsies were recorded. Ipsilateral breast tumor recurrences (IBTRs) diagnosed during follow-up were identified and classified as true recurrence or new primary disease. A competing-risk model was used to estimate the cumulative incidence of IBTR accounting for death before IBTR as a competing risk. RESULTS. The final study sample included 112 patients (median age, 71 years). A total of seven of 112 (6.3%) patients had a minor AE; no moderate or major AEs occurred. A total of 110 of 112 cryoablation procedures (98.2%) were technically successful. During a median follow-up of 2.0 years, 22 of 110 patients (20.0%) underwent biopsy for suspicious imaging findings in the ipsilateral breast, which yielded benign concordant findings in nine of 22 patients (40.9%) and IBTR in 12 of 22 patients (54.5%). Overall, 12 of 110 patients (10.9%) experienced IBTR, including seven with true recurrence and five with new primary disease; three of 12 patients (25.0%) with IBTR had received earlier adjuvant or neoadjuvant therapy. When death was accounted for as a competing risk, the cumulative incidence of IBTR was 5.3%, 12.2%, and 18.2% at 1, 2, and 3 years, respectively. CONCLUSION. In select individuals with unfavorable patient or tumor characteristics, breast cancer cryoablation provides a safe alternative to surgery and has good outcomes. These findings may be particularly relevant in patients who are also poor surgical candidates. CLINICAL IMPACT. Breast cancer cryoablation can be safely applied in a larger patient populations than those defined by clinical trial inclusion criteria.
引用
- Oueidat K, Baird GL, Barclay-White B, et al. Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multiinstitutional Study. AJR Am J Roentgenol. 2024. PMID: 38984781. doi:10.2214/AJR.24.31392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。